ERJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Permissions
Right arrowRequest Permissions
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Buccheri, G
Right arrow Articles by Ferrigno, D
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Buccheri, G
Right arrow Articles by Ferrigno, D
Eur Respir J 1994; 7: 1350-1364
Copyright © ERS Journals Ltd 1994


Original Articles

Prognostic factors in lung cancer: tables and comments

G Buccheri and D Ferrigno

Prognostic factors (PF) have a pivotal role in Clinical Oncology. They are helpful in the selection of treatment, provide insights into the disease process and the therapeutic response, and are fundamental in the design of clinical trials or in the interpretation of data from the literature. The number of possibly useful PFs in lung cancer is large (certainly more than one hundred). This paper attempts to provide a comprehensive listing of PFs and other variables potentially associated with outcome of lung cancer. This is achieved using tables, where studies relevant to each PF are referenced in relationship to their results, statistical power, type of analysis, number of variables incorporated in multivariate tests, and cell type. Tables include the outcome of an extensive retrieval of the literature and indicate visually where much of the evidence resides for the contribution of a variable to prognosis. Each table is briefly discussed and systematically comprises one group of PFs. Among the many pinpointed, the best predictive models still belong to studies based on clinical and routine laboratory data. Recent researches have clarified the role of new PFs (such as the biological factors); others (e.g. quality of life measures, the serum content of acute phase reaction proteins or the pathological evidence of tumour neoangiogenesis) might be recognized as important in the future. Like infinity, the fate of the individual patient will never become a completely measurable entity. However, as the discovery of new PFs proceeds, the assessment of the future prospects for patients is becoming more reliable.


This article has been cited by other articles:


Home page
Ann OncolHome page
T Berghmans, M Paesmans, C Mascaux, B Martin, A-P Meert, A Haller, J-J Lafitte, and J-P Sculier
Thyroid transcription factor 1--a new prognostic factor in lung cancer: a meta-analysis
Ann. Onc., November 1, 2006; 17(11): 1673 - 1676.
[Abstract] [Full Text] [PDF]


Home page
ThoraxHome page
L Dertsiz, G Ozbilim, Y Kayisli, G A Gokhan, A Demircan, and U A Kayisli
Differential expression of VASP in normal lung tissue and lung adenocarcinomas
Thorax, July 1, 2005; 60(7): 576 - 581.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
G. Buccheri and D. Ferrigno
Lung cancer: clinical presentation and specialist referral time
Eur. Respir. J., December 1, 2004; 24(6): 898 - 904.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
P. J. Mazzone, T. Mekhail, and A. C. Arroliga
Is Lung Cancer in the Nonsmoker a Different Disease?
Chest, August 1, 2004; 126(2): 326 - 329.
[Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
G. Buccheri and D. Ferrigno
Identifying patients at risk of early postoperative recurrence of lung cancer: a new use of the old CEA test
Ann. Thorac. Surg., March 1, 2003; 75(3): 973 - 980.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
M. D. Brundage, D. Davies, and W. J. Mackillop
Prognostic Factors in Non-small Cell Lung Cancer* : A Decade of Progress
Chest, September 1, 2002; 122(3): 1037 - 1057.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
E. Steels, M. Paesmans, T. Berghmans, F. Branle, F. Lemaitre, C. Mascaux, A.P. Meert, F. Vallot, J.J. Lafitte, and J.P. Sculier
Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis
Eur. Respir. J., October 1, 2001; 18(4): 705 - 719.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
D. Ferrigno, G. Buccheri, and I. Ricca
Prognostic significance of blood coagulation tests in lung cancer
Eur. Respir. J., April 1, 2001; 17(4): 667 - 673.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
G. Buccheri and D. Ferrigno
Prognostic Value of Stage Grouping and TNM Descriptors in Lung Cancer
Chest, May 1, 2000; 117(5): 1247 - 1255.
[Abstract] [Full Text] [PDF]


Home page
Arch Intern MedHome page
A. Vigano, E. Bruera, G. S. Jhangri, S. C. Newman, A. L. Fields, and M. E. Suarez-Almazor
Clinical Survival Predictors in Patients With Advanced Cancer
Arch Intern Med, March 27, 2000; 160(6): 861 - 868.
[Abstract] [Full Text] [PDF]


Home page
Arch Gen PsychiatryHome page
H. Faller, H. Bulzebruck, P. Drings, and H. Lang
Coping, Distress, and Survival Among Patients With Lung Cancer
Arch Gen Psychiatry, August 1, 1999; 56(8): 756 - 762.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1994 by the European Respiratory Society.